Lindenhofspital, Radiation Oncology, Bern, Switzerland 2 Klinikum rechts der Isar, TUM, Radiation Oncology, Munich, Germany Introduction: Superficial hyperthermia (sHT) combined with radiotherapy (RT) has proven efficacy in the management of locally recurrent breast cancer (LRBC). Response rates and local control are considerably influenced by the extension of LRBC. Tumor extensions should be classified to allow for well-designed studies and a better comparison between studies. We therefore suggest a classification using 5 stages and present our results according to these stages. Methods: This retrospective analysis includes a total of 140 patients with pre-irradiated LRBC, all subsequently treated with combined hypo-fractionated re-RT of 20 Gy total dose (5 × 4 Gy, 1x/week), delivered 1-4 min after contact-free, thermography-controlled water-filtered infrared A hyperthermia (wIRA-HT). 29 patients had microscopic disease, 111 presented macroscopic disease. The 5 stages of LRBC were defined as follows:
Stage 0: microscopic disease (after resection).
Stage I: limited to homolateral chest wall, extension smaller 12 × 12 cm.
Stage II: limited to homolateral chest wall, not passing mid line or median axillar line, infraclaviculär and superior rib bow, extension larger 12 × 12 cm.
Stage III: homolateral chest wall and supraclavicular fossa and/or contralateral chest wall and/or abdominal wall.
Stage IV: stage III + extension on the back (cancer en cuirasse). Updated information on duration of local control data and progression free survival as well as re-RT-related toxicity data of these patients (including stage 0) will be presented. No thermal skin damage (TSD) ≥ grade 2 was observed. Conclusions: Response rates are greatly dependent on the extension of LRBC. Our suggestion aims at initiating a discussion in ESHO, STM, and ASHO to agree on a classification of LRBC-extensions. Our data show a "cut off" of local control at stage IV with only one patient achieving a CR. Compared to literature data, many of our patients presented with locally very advanced stages, e. g., 44% (49/111) had stage III/IV. Especially these patients can benefit from reRT immediately followed by sHT.
Results:

OP 11
Feasibility of re-irradiation plus hyperthermia for recurrent pediatric sarcoma -an In Silico study diated patients. Positive results have been reported for chemotherapy and hyperthermia (HT), but re-irradiation combined with HT has not been investigated so far, although it is a proven treatment strategy for indications in adults. Objectives: We investigated the theoretical feasibility of re-irradiation+HT for recurrent pediatric sarcoma in the pelvic region and extremities. Methods: All 47 recurrent pediatric sarcoma diagnosed at the AMC since 2002 were evaluated. Patients not previously irradiated and locations other than the pelvis and extremities were excluded. Two patients with a previously irradiated sarcoma in the pelvis and two in an extremity were eligible. HT and re-irradiation treatment plans were simulated for realistic low dose 23 × 2 Gy treatment schedules and weekly HT. The radiosensitizing effect of HT was quantified using biological modelling with a temperature-dependent change in the α and ß parameters of the Linear Quadratic model. The possible effectiveness of re-irradiation+HT was estimated by calculating the equivalent radiotherapy dose distribution.
Results: Treatment planning showed that pelvic locations and extremities can be heated effectively in children. Evaluation of the equivalent dose distributions indicated that hyperthermic radiosensitization can be quantified as a target-selective additional D95% of typically 10 Gy in the PTV, thereby realizing a possibly curative dose of 54 Gy, without substantially increasing the equivalent dose to organs at risk (e. g. bladder, rectum). Fig. 1 shows example treatments of a pelvic and an extremity tumor.
Conclusion:
This planning study showed that re-irradiation+HT is a theoretically feasible and effective treatment for recurrent pediatric sarcoma in the pelvic region and extremities. Based on these positive results, evaluation of the clinical feasibility is worthwhile. Introduction: Loco regional breast cancer recurrences may be the cause of severe suffering when uncontrolled, without being life-threatening at short time. The therapeutic effect of Hyperthermia (HT) in association with Radiotherapy (RT) has been extensively demonstrated in a wide variety of oncological settings, playing an important role in the treatment of recurrent disease, previously irradiated. The Celsius TCS 42 System is a non-invasive medical equipment of local capacitive hyperthermia that, through its 2 active electrodes, emits a radiofrequency of 13,56 MHz, which allows to raise the temperature of the tumour in a selective and focused way. Objectives: To describe the initial Portuguese experience in treating locoregional breast cancer recurrences with radiotherapy-reirradiation-combined with local capacitive hyperthermia.
Patients and methods:
We retrospectively analysed the data of 12 patients, who underwent RT and HT, between May 2016 and August 2017. All patients were treated with IMRT technique and the same radiation schedule of 4 Gy twice weekly, to a total of 32 Gy, with an interval of 3 days between fractions, and one hour of HT, once a week. The time interval between RT and HT session was 30 minutes. Results: The treatments were well tolerated with acceptable toxicity. The median follow-up period was 9 months. The skin reaction was moderate to marked erythema in all cases, treated with conservative measures. The complete response rate was 83%, which confers a valuable local palliation and may be an option for patients for whom there are no longer valid therapeutic proposals to offer.
Conclusion:
The combination of RT with capacitive HT results in a complementary tumoricidal effect and has been used in the treatment of such lesions, with a high rate of response and acceptable toxicity.
A longer follow-up period is necessary to evaluate late reactions and duration of remission.
Capacitive hyperthermia OP 13
Survival of cervical cancer patients with or without associated HIV infection and treated with modulated electrohyperthermia combined with chemo-radiotherapy Introduction: Survival rates of cervical cancer patients treated in low resource settings have been estimated to be up to 50% lower than in developed countries. Objectives: We report on preliminary 2-year survival results for the ongoing Phase III trial investigating the effects of the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy protocols for HIV positive and negative cervical cancer patients in Johannesburg, South Africa.
Patients and methods: Patients classified as FIGO stage IIb to IIIb were randomised to either Intervention or Control group (CG)
. HIV positive patients on antiretroviral medication and with a CD4 count <200 cells/µL were eligible to enter the trial. All participants were prescribed chemo-radiotherapy (CRT). Participants in the Intervention group (IG) were prescribed, in addition to CRT, two mEHT treatments per week (130 W). Absolute survival at 6 months is reported (Chi2). Two-year survival analysis was estimated using Kaplan-Meier method. The study was approved by the local Human Research and Ethics Committee.
Results: 51% of participants are HIV positive and two-thirds (66.6%) are in Stage III of disease. 160 participants have data available for analysis at 6 months: Survival is 91% (n = 70) in the IG vs 81% (n = 90) in the CG. Complete response rate is better (47%;n = 33) in the IG versus the CG (32%;n = 27). 70 participants have data available for 2-year survival analysis. In a pre-specified per-protocol analysis of participants who completed treatment, 2-year survival was more likely in the IG (78% vs 65%; Prob>chi2 = 0.0334; adjusted for age). Progression free survival, adjusted for age, is also more likely in the IG (76% vs 61%; Prob>chi = 0.0317). There is no significant difference in survival in the HIV negative compared to the HIV positive participants (Prob>chi2 = 0.8657). We expect more data to be available at the time of the presentation and this will be included in the report in order to expand the data set.
Conclusion:
Early results show 6 month and 2-year survival, as well as 2-year disease free survival, are more likely to be achieved in the group treated with mEHT combined with CRT, regardless of their HIV status. Further follow up of participants is required to confirm these results.
Declaration:
The device being used is supplied by Oncotherm GmbH. Study is funded by the National Research Foundation of South Africa.
Strahlenther Onkol (2018) 194:471-507
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Hyperthermia combined with radiotherapy and chemotherapy in the locally advanced, recurrent or metastatic disease
S. Maluta
University of Verona, Verona, Italy
Introduction: From 2013 to 2017 63 evaluable patients affected by diffuse tumors were treated by using chemotherapy and/or radiotherapy combined with hyperthermia, in the most of case with palliative intent.
Patients and method:
Patients were affected by locally advanced, recurrences and/or metastatic disease and they were treated by following the ESHO guidelines. Indications were distinguished between EBM level -1 (breast recurrence, sarcoma, head and neck, cervix and bladder cancer) and EBM level-2 and 3 (primary and metastatic liver cancer, lung, kidney, prostate, esophagus and rectal cancer). We used two different equipments for superficial (microwaves of 434 MHz, max output 200 watt) and deep hyperthermia (radiofrequency of 13.56 MHz, max output 600 watt). Usually a session per week was delivered, monitoring temperature and kilocalories (until a max of 43 °C and 305 kilocalories in 60 min). Both system have an integrated cooling system. Results: Primary end points were clinical response and side effects and results were evaluated by using RECIST Criteria. Objectives: The aim of this work is to present actual status of ongoing clinical trial. The primary endpoint of the study is to estimate the rate of late Grade ≥3 gastrointestinal (GI) and genitourinary (GU) toxicities related to salvage treatment for locally recurrent prostate cancer after previous external beam radiation therapy.
Material and methods:
The patients are recruited in Center of Oncology in Krakow and Center of Oncology in Warsaw (Poland) and in University Hospital in Erlangen (Germany). In this trial, the dose prescribed to the PTV will be 30 Gy in three 10 Gy fractions spaced 21 days apart for HDRBT (the most common fractionation scheme in Poland) and 60 Gy in 2 fractions spaced 28 days apart for PDRBT (scheme from Erlangen). In both protocols, the brachytherapy will follow interstitial hyperthermia treatment. Interstitial hyperthermia (IHT) treatment is scheduled before every brachytherapy fraction and it should end no more than one hour before the start of irradiation. Hyperthermia will be carried out in accordance with the QA guidelines published by the RTOG for interstitial hyperthermia. Objectives: To report institutional outcomes for the use of local hyperthermia (HT) in treatment of advanced cervical cancer Material and methods: To determine clinical benefit of local HT overall survival (OS), disease free survival (DFS) and response rate (RR) were assessed in randomized trial. All patients (n = 83) received external beam radiation and low-dose-rate interstitial brachytherapy. Forty patients from them during radiotherapy (RT) additionally received 10 sessions of local hyperthermia (HT). Heating of tumor site was provided by Celsius TCS device. Sessions of local HT with gradually increasing of thermal dose were performed three times per week. Results: Two-year overall survival in group of patients after RT without HT (n = 43) was 70 ± 1,0%, in group of patients who received RT with HT (n = 40)-86 ± 7%, (p = 0,5790), DFS in group without HT was 44,8 ± 1%, with HT-70,4 ± 9% (p = 0,4157). Complete response in former was 65,1% (n = 28), in latter 82,5% (n = 33).
Conclusion:
The preliminary results of randomized trial demonstrate some clinical benefit of local HT for patients with advanced cervical cancer in two-year OS, DFS and RR, but there was no statistically significance. The trial and patients recruiting is going on. 
Cinical trials session
Objectives:
The prognosis for patients with pancreatic cancer after curative resection is improved by adjuvant chemotherapy in terms of survival. We aimed to determine the efficacy and safety of gemcitabine and cisplatin combined with regional hyperthermia (RHT) as salvage treatment for patients with pancreatic cancer who failed adjuvant gemcitabine chemotherapy.
Material and methods:
Patients with recurrent disease who had undergone curative resection of pancreatic cancer followed by standard adjuvant gemcitabine chemotherapy were eligible. Patients were to receive salvage chemotherapy consisting of gemcitabine (1000 mg/ sqm) and cisplatin (50 mg/sqm) combined with RHT every two weeks for eight cycles. Toxicity was assessed according to CTC criteria and ESHO guidelines. TTR was defined as time from start of adjuvant gemcitabine therapy to first relapse. TTP was defined as time from start of salvage gemcitabine-cisplatin plus RHT until second progression. Relapse-free survival (RFS) was defined from start of adjuvant chemotherapy until progression or death with first relapse not considered as an event. Overall survival (OS) was defined from first diagnosis until death. Endpoints were analyzed according to Kaplan-Meier. Introduction: Neoadjuvant chemotherapy is considered to improve overall survival for patients with locally advanced high-risk soft tissue sarcoma (HR-STS). Thereby standard anthracyclines and IFO outperform the newer, histology tailored approaches with GEM/TAX for undifferentiated pleomorphic sarcoma (UPS), high-dose ifosfamide for synovialsarcoma, ETO/IFO for malignant peripheral nerve sheath tu mors (MPNST), GEM/DTIC for leiomyosarcoma. Only trabectedin for myxoid leiomyosarcoma was not inferior. Objective: To summarize recent result and activities for the use of RHT in soft tissue sarcoma. Results: Regional hyperthermia (RHT) combined with DOX/IFO/ ETO as neoadjuvant therapy for HR-STS has shown to improve survival after 11-years follow up of the EORTC-62961 ESHO-RHT-95 trial (Issels et al. JAMA Oncology 2018). As the patients in the control arm have been treated also with the same chemotherapy regimen and as all patients have received the best available local therapy consisting of surgery and radiotherapy, RHT combined with anthracycline/ifosfamide containing therapy should be considered as the most effective treatment modality in this setting. ETO is not considered to be a first line drug for conventional STS and is associated with the risk of secondary leukemia. Therefore it was omitted for the current treatment protocol of our Sarcoma Center (SarKUM). Subsequent analyses have shown equal effectivity of both regimens (Schuebbe et al. DKK 2016) .
RHT plays also a role in second-line chemotherapy regimens. For the combination with IFO/CARBO/ETO (mini-ICE) in 110 anthracycline pretreated patients a progression-free rate > 40% had been observed (Bücklein et al. MS submitted). For patients not suitable for ifosfamide treatment, RHT has been successfully combined with anthracycline/DTIC also in the neoadjuvant setting. In patients where surgery is not amenable the combination of RHT with radiotherapy can provide long term tumor control. The rationale of inhibiting DNA-repair by RHT and thereby increasing cytotoxicity of DNA double strand breaks causing agents like trabectedin is currently investigated in a randomized phase II trial (Hyper-TET). Novel doxorubicin-containing thermosensitive liposomes have shown significantly improved tumor responses in feline sarcoma. This technology bears the potential to overcome standard anthracyclines for the neoadjuvant therapy of locally advanced HR-STS. Conclusion: An overview of the most recent achievements and developments of RHT for the treatment of STS will be given. The distribution of the 115 pancreatic cases treated reflects no relevant differences in descriptive data. We specially analyze the 57 patients in the FUS-HIFU plus chemotherapy group. Clinical responses (ablation obtained) were 82% in all cases. We obtained 12 complete responses (21%) at the end of the combined treatment. Major complications included severe pancreatitis (2), skin burning grade III that required plastic surgery (2), duodenal perforation (1). One patient died from a delayed duodenal perforation. Median Survival is 23 months (6 mo-4.3 year) and Overall Percent Survival is 18% at 5 years follow up. Survival analysis between the two cohorts of patients shows a statistically significant benefit for the group of patients treated with FUS-HIFU plus chemotherapy (p = 0.0025). Hazard ratio is 0.45 Conclusions: FUS-HIFU is an effective and safe ablation of malignant liver and pancreatic tumors. In liver lesions, difficulties related to available devices makes it too cumbersome for accessible lesions at present compared with other ablations available. Access to deep lesions shows an opportunity for this system to increases its possibilities of use. In pancreatic tumors, compared with a similar cohort of patients treated a same hospital, it shows a clear survival advantage in non resectable stage III and IV cancer. These results encourage us to engage our efforts towards a Randomized Multicenter Study. Hyperthermic tumor ablation needs to be considered as group of oncological therapies along with Medical, Radiation and Surgical Oncology and re-considered at the light of this experience. Keywords: Interventional oncology, High-intensity focused ultrasound ablation, FUS, HIFU, Cancer, Liver cancer, Primary hepatic cancer, Hepatocellular carcinoma, HCC, Hepatic metastases, Pancreatic cancer, Chemotherapy, Hyperthermic tumor ablation
Biology session OP 26
In vitro testing of antitumor efficacy of modulated electrohyperthermia in C26 colorectal adenocarcinoma model set up and optimized an in vitro model for assessing the efficiency and molecular background of this process. Methods: Confluent C26 mouse colorectal adenocarcinoma cell cultures were treated at 42 o C using mEHT for 2 × 30 min or 2 × 60 min, respectively leaving 120 min intervals between interventions. After 1, 3, 9 and 24 hrs, stress response, apoptosis and growth signaling related markers were detected compared to untreated control cultures, furthermore indication for stem-cell survival was performed with clonogenic assay. The effect of combined 2 × 30 min mEHT and 1 µM doxorubicin treatment was also tested. Result: Tumor damage rate of ~50% (LD50) was achieved after 2 × 30 min mEHT treatment, while 2 × 60 min killed the majority of tumor cells. After 1 and 3hrs pro-apoptotic mRNA levels were increased and anti-apoptotic rates were decreased. At 24 hrs significant translocation of phosphatidyl-serine to the outer cell surface detected with annexin V flow cytometry indicated massive apoptosis. Elevated levels of heat stress induced Hsp70 and calreticulin, as well as cleaved caspase-3 and cytoplasmic phospho-ERK1/2 proteins were also revealed in situ. Stem-cell predictive colonies were also significantly reduced after mEHT treatment using colony forming assays. Combination of mEHT and doxorubicin treatments caused major reduction in cell viability compared to each monotherapy.
Conclusion:
Our results indicate that mEHT can induce irreversible cell stress leading to apoptosis even in tumor stem cells and cause deregulated cell growth in C26 colorectal carcinoma cultures. Synergistic effect of mEHT and chemotherapy support feasibility of using electro-hyperthermia for complementing cytotoxic tumor therapy.
This study has been supported by the Hungarian National Research, Development and Innovation Office (NVKP_16-1-2016-0042).
OP 27
Malign cell survival -comparing hyperthermia via incubator with hyperthermia via EM fields -exciting at firstdisappointing at last Introduction: All commercial loco regional hyperthermia devices use electromagnetic power (be it radiation or capacitative) to generate the heat. Thus we may not be able to differentiate between pure temperature effects and effects due to influences of the electro-magnetic field.
Objectives: Repeatingly there exists rumor that EM effects may be an as influential cause or account even more than the pure temperature effect. This thesis was to be tested.
Material and methods:
A series of different malign cell lines were taken to three identical samples and put to the incubator at 370 C. The first sample was taken once a day for consecutive four days and been put in another incubator at 420 C for 30 min. The second sample was taken in a capacitative hyperthermia devices and as well exposed to max 420 C for a period of 30 min. The third sample was left untreated. All samples were taken once a day to measure cell survival via ATP-luminescence acc.to Andreotti.
Results:
The first series of cell lines showed least cell survival in the first samples (put in the incubator), however after four days a pattern could be observed that the second sample (electro hyperthermia) suddenly dropped in cell survival significantly below the sample of the incubator and the control sample. However what in the beginning looked as interesting results could not be consistently reproduced in the repetition of the experiments. Conclusion: One ought to be very cautious in setting claims of therapeutic benefits due to electro-magnetic effects on malign cells. Still it remains an unproven speculation and it would be wise to associate hyperthermia only with claims that can be proven and reproduced. Otherwise the doubtless potential of hyperthermia will be harmed again in the eyes of the majority of oncological clinicians.
OP 28
Temperature dependent effectiveness of chemotherapeutic agents in colorectal cancer cell lines The first in vitro experiments show more reduction in cell viability after RKO cells were incubated with oxaliplatin during 1 hour at 41 °C compared to 37 °C (Fig 1 A) . RKO cells incubated with cisplatin or mitomycin C also showed more reduction in cell viability when treatment is combined with hyperthermia, although the cell viability was less decreased compared to the results with oxaliplatin ( Fig  1B, 1 C) . Other chemotherapeutics agents, 5-FU and gemcitabine, did not significantly reduce the cell viability in RKO cells when combined with hyperthermia treatment.
Conclusions:
Results show clearly enhanced TER values for oxaliplatin, cisplatin and mitomycin C in the in vitro experiments. Next step is to confirm these in in vivo experiments, which will be performed in a PMCRC rat model by transplanting tumor fragments into the abdomen of rats to develop carcinomatosis in the abdomen. HIPEC will then be performed at different temperature levels with clinically relevant doses, after which animals will be sacrificed to determine the tissue penetration depth of oxaliplatin and the other agents.
OP 29
Analysis and simulation of the response of 3D tumour spheroids to combination treatments of radiation and hyperthermia S. C. Brüningk, I. Rivens, S. Nill, U. Oelfke, G. ter Haar
The Institute of Cancer Research, Radiotherapy and Imaging, Sutton, United Kingdom
Introduction: Thermo-radiosensitisation offers the possibility of successful treatment of radio-resistant tumours. However, tumour response heterogeneity, due to intrinsic, or microenvironmental factors, may influence treatment outcome. 3D tumour spheroids allow the study of these effects in a more physiological environment than 2D cultures.
Objective: We present a systems oncology framework, based on experimental data, to study the response of 3D cultures to radiotherapy (RT) and hyperthermia (HT), and point out important differences with 2D models. Materials and methods: A cellular automaton model for RT and HT treatments [1] was extended to spheroid simulation. This included modelling of 3D geometries, oxygen diffusion, treatment specific cell death mechanisms and cell clearance. For simulation calibration and validation, three human cancer cell spheroids were tested for their response to RT (0-20 Gy), HT (0-240 CEM), and combinations thereof. Growth was monitored for 25 days using a cytometer. Immunohistochemical staining allowed analysis of distributions of viable (KI67), hypoxic (pimonidazole), and necrotic (haematoxylin and eosin) sub regions. For comparison, 2D clonogenic and resazurin assays were performed. Results: The framework was first calibrated by modelling untreated spheroids while accounting for the influence of hypoxia induced necrosis at their core. Simulations were matched with experimental growth curves and histological sections, as well as with an analytical oxygenation model [2] (figure 1). For treatment response modelling it was essential to consider the influence of the underlying cellular response mechanisms, such as necrosis, mitotic catastrophe, or cellular senescence. In contrast to 2D cultures, the clearance of dead cells was an important additional step in order to fully capture the dynamic response of 3D populations. This may explain response differences observed in growth delay between 2D and 3D cultures (figure 2). Conclusions: It was found that cellular treatment response may differ with culture systems, i. e. 2D or 3D. The proposed framework provides an important step towards in vivo modelling of RT and HT and allows for optimization of treatment combinations and scheduling under physiological conditions. Objectives: It has been suggested that combining hyperthermia with intermediate linear energy transfer (LET) radiation (i. e., protons) would have anti-tumor activity equivalent to that seen with high LET radiation (i. e., carbon ions). This is based primarily on in vitro observations. We now present in vivo results showing that even low LET (i. e., photons) combined with hyperthermia is as good as, if not better than, high LET radiation. Methods: Non-anaesthetised female CDF1 mice with a 200 mm 3 C3H mammary carcinoma growing in the right rear foot were used in all experiments. Treatments were performed with the tumor bearing leg immersed in a water bath maintained either at 25 O C for radiation (240 kV X-rays) alone or with heating at 41-43 O C for 30 or 60 minutes. For the simultaneous combination of radiation with heat, the radiation was administered in the middle of the heating period. The percentage of mice showing local tumor control 90 days after treatment with graded radiation doses was recorded and following logit analysis of the radiation dose response curve, the TCD50 value (radiation dose causing tumor control in 50% of mice) was estimated. Results: The TCD50 value following irradiation with photons alone was found to be 54 Gy. This was decreased by heating, such that the therapeutic enhancement ratios (TER, ratio of TCD50 values for radiation alone to radiation and heat) increased with heating time and temperature; the TER values following heating for 30 minutes at temperatures of 41.0, 41. . One-way ANOVA comparison of group means was performed, and a P < 0.05 was considered significant.
Results:
The TGT5 for the control group was 6.6 days (± 0.2). For the groups treated with anti-CTLA4 ab on day 1, days 1 and 3, or days 1-4, the TGT5 was 5.8 days (± 0.4), 5.8 days (± 0.4) and 6.8 days (±0.3). There were no significant differences between treated animals and controls. In the heat group, the TGT5 was significantly increased to 11.1 days (± 0.9). This was further increased when heat was combined with anti-CTLA-4 ab to 11.6 days (± 1.2) for treatment on day 1, 12.9 days (± 2.7) for days 1 and 3, and 15.4 days (± 0.8) for days 1-4. The values for day 1 and 1 and 3 were not significantly different from heat alone, but the heat and anti-CTLA-4 ab on days 1-4 was significantly increased (p = 0.004). One mouse remained without signs of recurrence after 3 months, and is not included in the statistics.
Conclusion:
As the C3H mammary carcinoma is insensitive to treatment with CIs, it is to be considered as a non-immunogenic "cold" tumor. However, when treated with heat, the tumor becomes "hot"; it gets CI sensitive to anti-CTLA-4 ab administered on days 1-4. Our data thus clearly show the potential benefit of combining hyperthermia and specific CIs to improve tumor immunogenicity. A novel study is currently investigating T cell up-regulation and tumor infiltration based on histology.
OP 33
Hyperthermia as part of multimodal immunotherapy for children with DIPG tween subsets and complete sets of sensors were evaluated in terms of overall minimum (Tmin) and maximum (Tmax) temperature, as well as T90 and T10, which are the 90th and 10th percentile of the temperature measurements, respectively. Results: 80 patients were included, yielding a total of 400 hyperthermia sessions. Median ∆T between subsets (8-126 sensors/session) and complete sensor sets (60-147 sensors/session) was <0.01 °C for T90 with a 95% confidence interval (CI) ≤0.5 °C, when >50 sensors were used. (Fig. 1) . Subsets of <10 sensors result in underestimation of Tmax up to -2.1 °C (∆T 95% CI), which decreased to -0.5 °C when >50 sensors were used. Thermal mapping (8-21 probes with 60-147 temperature points) yielded a median ∆T < 0.01 °C for both T90 and Tmax, with an ∆T 95% CI of -0.2 °C and 0.4 °C, respectively. The detection rate of Tmax ≥43 °C is ≥85% while using >50 stationary sensors or thermal mapping (Fig. 2) . Conclusion: Adequate monitoring of the skin temperature distribution during superficial hyperthermia, (e. g. identification of local hotspots and T10 and T90 temperature distribution descriptors within ± 0.5 °C), requires the use of >50 stationary sensors or thermal mapping points per 400 cm2 applicator.
OP 36
On the experimental validation of deep hyperthermia devicesstudy of representative phantoms Introduction: Simple phantoms are often used both in experimental and numerical studies devoted to the validation and optimization of hyperthermia devices [1] [2] [3] . These phantoms help in the settlement of the devices excitation to reach a definite goal, i. e., to focalize the electromagnetic power absorption in definite positions within the body without inducing hot spot in other positions. Their simplicity allows experimental verification by measuring the electric field or the temperature increase and performing simple comparisons with numerical results. The question is how representative are simple phantoms with respect to the electromagnetic and temperature distribution achievable by hyperthermia devices in the human body. Additionally, what are the tissues and organs that should be considered to make these phantoms representatives and, at the same time, keep them as simple as possible for easiness of use.
Methods: Simulations were performed considering a radiative deep hyperthermia system and several phantoms. In particular, the model of a 26-year-old woman was considered [4] both as non-homogeneous and with increasing simplifications of the considered tissues. A phantom with anthropomorphic shape and composed by uterus, bladder, bone of the ileum, muscle and sub-cutaneous fat was considered also.
Comparison was made on the percentage electromagnetic power absorbed by the different tissues in all considered cases Results: The obtained results show that the geometry and dimension of the body models and of their internal organs don't change the absorbed power distribution. On the contrary, body composition, i. e. the tissues and organs which are considered into the body, influence the absorbed power distribution. In particular, the presence of fat, including both the subcutaneous one and the visceral fat that surrounds the most internal organs, proved to change the percentage electromagnetic power absorbed by the different organs.
Conclusions: Phantoms to be used in validation studies as well as in quality assurance procedures for deep hyperthermia systems should include both subcutaneous and visceral fat to correctly evaluate power absorption into deep body organs. Table 1 ). For this purpose, 43 consecutive patients treated in our Department were analyzed and the results are reported according to the appropriate indicators. Results: Considering the analyzed indicators, we obtained that the number of treatments in which temperature measurements is performed during patient treatment is 100% and a minimum of five different locations to measure skin temperature every minute during superficial hyperthermia are used according to the European Society for Hyperthermic Oncology technical committee; the number of complete response (CR)/> G2 toxicity was 31% in mean from 6 to 36 months; the percentage of number of patients that complete the total hyperthermia treatment is 86% and patient satisfaction with the staff obtained a Introduction: Our paper deals with SAR distribution created by a superposition of EM expositions done contemporary by external and interstitial applicator. Three different cases are numerically and experimentally studied and compared in this paper. In the first case we will describe the shape of SAR distribution created only by monopole antenna, which represents interstitial applicator. In the second case we will discuss the SAR distribution created only by external microwave stripline type applicator with TEM mode. In the last case we will describe a superposition of SAR distribution created by EM expositions done contemporary by external and interstitial applicator. Both ap- plicators are excited at the same frequency (f = 434 MHz), power and phase. Methods: In all these three cases homogeneous agar phantom representing a muscle tissue (εr = 54, σ = 0.8S/m) with dimensions 140 × 140 × 74 mm was used. In here described studies the microwave stripline applicator was located on the surface of this agar phantom instead the monopole antenna was situated 4 cm deep under the surface of the agar phantom. Both applicators were powered coherently, which allow us to take advantage of their mutual interference. Simulations of the shape of SAR distribution have been done by the FDTD method, in our case it was done by a id of SEMCAD XEM Field simulator. Results: Both numerical and experimental evaluations of superposition made by exposition by both applicators were compared. In presentation it will be demonstrated a very good homogeneity in temperature increase between aperture of the external applicator and position of interstitial applicator. Acknowledgment: This study was supported by by a grant from the Czech Science Foundation, number 17-20498 J: "Non-invasive temperature estimation inside of human body based on physical aspects of ultra-wideband microwave channel".
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Verification of self-calibration algorithms for phased array applicator
M. Zanoli, H. Dobšíček Trefná
Chalmers University of Technology, Electrical Engineering, Göteborg, Sweden
Introduction:
In microwave hyperthermia (MW-HT), treatment planning determines the steering parameters for a phased array to yield appropriate tumor coverage and hot-spot suppression. In real HT systems, however, such arrays are subjected to mismatches, which might not be considered in the models used in treatment planning. While certain mismatches can be addressed via channel calibration, those occurring inside the array are more difficult to predict as they can vary during the treatment session itself. The effect of such mismatches can be as relevant as to disrupt the interference pattern. Objectives: This contribution proposes self-calibration (SC) as a solution for real-time compensation of various types of mismatches, such as different cable lengths, manufacturing tolerances, patient misplacement and air bubbles in the water bolus. Two SC algorithms have been designed for use with applicator arrays of arbitrary shapes.
Materials and methods:
The algorithms are based on comparison of simulated and measured S-matrices of the phased array. The extra time delays caused by various mismatches at each channel are then compensated accordingly. The verification of both algorithms includes virtual and experimental models of our neck applicator used in a setup with a patient model and a muscle phantom. The accuracy has been evaluated numerically by comparing the ideal E-field distributions with those obtained by introducing a set of randomly distributed mismatches to the applicator model. The proof-of-principle has then been demonstrated experimentally by means of temperature measurements.
Results:
Results indicate that at least one of the tested SC algorithms converge to the correct compensation solution with performances largely comparable and sometimes even exceeding those typical of an external calibration. Antenna offsets of ±5 mm and air bubbles about 1 cm big are well handled. Improvements can be done with respect to patient misplacement, which is compensated by the algorithm up to ±1 mm. Experimental results confirm the ability of the algorithm to restore focus shape. Conclusion: Self-calibration can be a valid solution for mismatch compensation in MW-HT. The potential real-time application of SC makes it a desirable candidate for use in clinical settings. Introduction: Hyperthermia treatment (HT) has been reported to sensitize cancer cells to chemotherapy and radiation therapy (RT), both in vitro and in vivo. Ultrasound (US) is able to generate HT in tissue precisely and noninvasively while temperature is controlled via MR imaging methods. In this study, we investigated the effects of US-HT in vitro to increase radio-sensitivity of human glioblastoma (T98G), prostate (PC-3), and head and neck cancer cell lines (FaDu and UTSCC-5).
Methods:
We have developed a high throughput in vitro US therapy system for sonication of 96 well µ-clear plates (Greiner Bio-One GmbH) possessing 96 individual piezoelectric transducers delivering acoustic energy to the individual wells by means of acoustic dry coupling (frequency: 1 MHz; intensity: 0.75 W/cm2). US-HT (40-45 °C) was generated for 20 min. As a control, thermoblock HT was performed. Real-time temperature was monitored by an infrared thermal camera (PI450, Optris GmbH). Cells were irradiated 15 or 60 min post HT treatment with a 150 kV X-Ray device (DARPAC 150-MC) for RT at dose of 10 Gy. Cellular metabolism (WST-1 assay), newly synthesized DNA (BrdU assay) and DNA double-strand breaks (gH2A.X assay) were evaluated post treatment. Results: Metabolic activity (NAD(P)H) decreased in US-HT group for all investigated cell lines (T98G: 72%, FaDu: 10%, UTSCC-5: 12.5%), revealing a higher efficiency of US-HT, compared to control HT group (T98G: 80%, FaDu: 79%, UTSCC-5: 96.5%). There was a greater reduction in NAD(P)H levels in T98G cells when RT was performed 15 min post HT(47% viable cells) compared to 60 min post HT (58% viable cells). Conclusion: Our preliminary data suggest that US-HT-RT had a greater treatment effect in all tested cell lines compared to thermoblock-HT-RT. This may be due to the additional biomechanical effects of US. The shorter time interval between HT and RT was also the most effective. Future studies will investigate the mechanisms of the combined treatment. Introduction: The Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor survival despite the many therapeutic strategies explored. Conventional radiotherapy remains the main treatment for GBM, but several clinical trials performed in the last decade suggest that hadrontherapy, especially with carbon ions, could be particularly promising.
Hyperthermia (HT) has been considered to be the most powerful way of sensitizing ionizing radiation, and the hypothesis that hyperthermia coupled with proton (PT) irradiation could mimic 12 C-ion therapy is currently investigated. Objectives: To evaluate the in vitro combined effects of HT coupled with different qualities of ionizing radiation (X-rays and protons) on the tumourigenic U-251MG human GBM cell line. Purpose is to define the determinants of radiosensitivity and to assess the optimal thermal dose and treatment sequence for planning the ensuing in vivo investigations in a xenogenic mouse model. Materials and methods: U-251 MG cells are being investigated for their radiosensitivity to X-rays and PT (in the range 1-8 Gy) and thermosensitivity (in the range 42-45 °C, 15-60 minutes) by means of clonogenic assay (either survival or delayed survival assay), cell-viability assay (MTT), apoptosis induction, cell-cycle analysis, micronucleus assay. A digital thermostatic bath was used for HT exposure; temperature was strictly monitored in dummy samples throughout the experiments. Results: U-251 MG cells displayed radioresistance, as demonstrated by the large shoulder on the survival curves, while they showed a good HT response (45.5% ± 2.1% surviving fraction after HT at 42.8 ± 0.1 °C for 60 min). The combined treatment X-rays and HT showed a large thermal radiosensitization in the shoulder region not dependent on the treatment sequence. Experiments with PT combined with HT are in progress.
Conclusion:
The achieved results are encouraging and show that HT could represent a promising approach to improve the response of GBM to radiation treatment.
Ultimate goal is to define the optimal treatment protocol for HT-PT combination to be used with the in vivo U-251 MG mouse model. Acknowledgements: This work is carried out within "TOP-IM-PLART" Project funded by "Regione Lazio", Italy.
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Contraindication for radiative deep regional hyperthermia for patients with large carbon implants Introduction: Hyperthermia with radiative heating to temperatures of 41-43 °C has shown to be a valuable sensitizer for radiation-and chemo-therapy in cancer treatment. In this study the influence on specific absorption rate (SAR) and temperature by carbon fiber reinforced polyether-ether-ketone (CFR-PEEK) implants which are used to replace titanium (TI) implants was investigated.
Methods:
The influence on SAR and temperature was investigated in three rods with identical diameter of 5.5 mm and length of 140 mm. The rods were made of a TI, CFR-PEEK and PEEK of which the TI and the CFR-PEEK are commercially available products for trauma and reconstructive surgery provided by icotec AG, Altstätten, Switzerland. For the SAR measurements the samples were placed inside an elliptic phantom filled with saline inserted in the SigmaEye applicator of the BSD-2000 3D deep hyperthermia equipment (Pyrexar Medical, Salt Lake City, USA). Inside the tube, a SAR probe (EASY4/MRI, SPEAG, Zürich, Switzerland) was moved along the samples and the relative SAR strength was recorded. For the temperature measurements, the samples were placed in a tissue equivalent gel phantom inside the SigmaEye applicator. The temperature rise following a power pulse of 1000 W for 5 minutes (pulse#1) was measured.
Results:
The SAR measurements parallel to the axis of the rods showed a clear increase of maximum relative SAR strength for both TI and CFR-PEEK but no increase for the PP and PEEK material. Relative SAR increased by 329% for TI and 297% for CFR-PEEK at the tips of the rod. Temperature measurements in the gel phantom showed a similar behavior with a maximum temperature rise at the tips of the rod up to 27 °C for both TI and CFR-PEEK and 3 °C for PEEK after pulse#1 (Fig. 1) . Conclusion: TI and CFR-PEEK show a similar influence on SAR and temperature in a deep hyperthermia treatment set-up. Thus CFR-PEEK implants, like metal implants, must be a contraindication for radiative deep hyperthermia treatment.
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Dual mode microwave ablation applicator Objectives: Microwave ablation (MWA) gains interest in the last decades as alternative treatment option for cancer patients with unresectable hepatic tumors. A further enhancement of this technology is proposed by a dual mode applicator for thermal ablation treatment with sensing capabilities designed to operate under MRI guidance with an operational frequency of 10 GHz.
Methods:
The additional sensing mode provides additional information for the interventional radiologist to achieve a more accurate localization of the targeted tumor and reduced number of insertions. It is realized by analyzing the reflection coefficient of the applicator that reveals information about the surrounding tissue around the tip of the applicator. Hence, an accurate positioning becomes possible by evaluating local permittivity changes of 15%-30% indicating the presence of tumors. Once a tumor is detected, the applicator can be switched from low power operation for diagnostics to the high power treatment mode and the input power is increased to perform thermal ablation. Results: Measurements of the dual-mode device with phantoms mimicking a dieletric contrast between healthy and malignant tissue reveal a minimum relative resolution of 3.4% that exceeds the required resolution in order to detect tumorous tissue. Moreover, temperature measurements of the applicator inserted into ex-vivo bovine liver tissue show a rapid temperature increase of the tissue close to the applicator of 130 °C after 4 minutes with a continuous wave input power of 20 W. The resulting lesion zone size is 2 cm^2.
Conclusion:
The dual mode concept presents an advanced technology for MWA tools with the advantage of providing information of the tissue state at the applicator that can be combined with MRI guidance to improve the positioning procedure during the intervention. Moreover, less power and treatment time is needed to achieve therapeutic temperatures due to the high frequency of operation.
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Fast clinically feasible MR sequences to map electrical tissue conductivity for improved accuracy in hyperthermia treatment planning (HTP) Objectives: Patient-specific electrical properties can be measured by MR-Electrical Property Tomography (EPT) [1, 2] . EPT-based conductivity σ values are essential for hyperthermia treatment planning (HTP) 1 . A transceive phase (Φ ± ) map must be acquired to reconstruct σ. Normally, a spin-echo (SE) is used. We evaluated faster alternatives for Φ ± and σ mapping: bSSFP [3] and PLANET [4] . Methods: MR measurements (3 T, Philips Ingenia, NL) were performed on a phantom and on a healthy volunteer's brain with the body coil for transmission, and a 15-channel receive head coil. Each technique was run with 5 different resolutions. Table 1 summarizes phantom properties and imaging parameters of SE, PLANET and bSSFP.
The precision of the measured Φ ± was assessed by fitting a 2D parabola to the inner compartment [5] . The RMSE was associated with Φ ± uncertainty, ∆Φ ± . This uncertainty was multiplied by the measurement time to derive the sequence efficiency. Finally, σ was reconstructed based on each technique by using phase-only EPT and transceive phase assumption [3] . Results: With respect to Φ ± , bSSFP was the most precise ( Fig. 1a ) and efficient technique (Fig. 1b) . Its efficiency out-performed PLAN-ET with factor 8, and SE with factor 20-34 at 1.5-3.75 mm, respectively. The σ-standard deviations in Fig. 1c confirmed the ∆Φ ± -trends shown in Fig. 1a .
The brain MRI was done at 2.5 mm resolution, where all techniques have comparable ∆Φ ± . The bSSFP Φ ± -map was mildly corrupted by local field variations, that were amplified during σ reconstruction. PLANET and SE had similar σ-maps, but PLANET was faster. Conclusion: PLANET intrinsically corrects for local field variations corrupting bSSFP, is precise and has clinically feasible scan times. Thus, PLANET seems a good candidate for brain σ EPT and could replace SE in the HTP imaging protocol. Introduction: Realistic region-based voxelfield models are needed for electromagnetic or thermal simulations. Tumor and organs-at-risk delineation should ideally be performed by experienced physicians. Creation of such models using special voxel-based segmentation editors is time consuming and often inaccurate. On the other hand, accurate and fast contouring state-of-the art platforms are widely-used for radiation therapy. However, the contours are coded by polygonal chains and not as segmented voxelfield data. Objectives: To create a fast algorithm to convert the standard output based on polygonal chains into a voxelfield data. Methods: Computed Tomography (CT)-scans were generated and clinical contouring was performed using the standard Varian Treatment Planning System (Eclipse Version 11.0). Open Source platforms "Plastimatch" (www.plastimatch.org) and Octave (www.gnu.org/software/ octave/) as well as Matlab 4.2016b were used. Results: A novel procedure was developed that consists of three main steps (steps → A/ B/C marked by blue/green/purple colors, resp., in Fig.  1 ): → A: Contouring in Eclipse; contours (in Fig. 1 1, 2, italic) coded in a DICOM-RT structure set file. Deciding which overlapping regions can be later overwritten by others ("Ranking info"). If parts of regions cannot be overwritten, non-overlapping sub-regions are created. → B: Plastimatch reads out the DICOM-RT file and writes it in a CTX format, sorting the data as polygonal chains structure by structure. → C. A self-writ- Fig. 1 P 08. Multi-Polygon-to-Voxelfield-converting procedure (a simplified example of two structures) Fig. 2 P 07 . Phantom and brain studies. For the phantom study each technique was evaluated at 5 different resolutions with respect to: (a) its uncertainty in the transceive phase ∆φ±; (b) its efficiency factor ∆φ± -t; (c) the standard deviation of its conductivity; (d) manually-delineated ROI inside the inner compartment (d, green circle) where ∆φ± and σ-SD were calculated. Note that a sequence performs best when the efficiency factor is low, i. e. fast acquisition time (t) and low ∆φ±. In (c) in the number of voxels in the ROI at resolutions>3 mm was insufficient to compute σ-SD values. For brain study, maps for the φ± and σ are shown for all the techniques at 2,5 mm resolution Strahlenther Onkol (2018) 194:471-507 ten Octave algorithm reads the CTX file and converts the contours into region-labelled voxelfield data (see also Fig. 2 ). Especially, it recognizes polygonal chains describing "holes" in regions. A Matlab algorithm performs a sub-region segmentation using Hounsfield unit thresholds, thus making the voxel model an optimal "mixture" of clinically contoured organs/regions and threshold-based segmented subregions. Conclusion: A procedure for fast and efficient generation of voxel models for a standard radiation therapy contouring platform was developed. No time-consuming additional segmentation in voxel-based editors is needed.
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SAR profiles generated with a capacitive hyperthermia system in a porcine phantom M. Beck, B. Chrozon, A. Lim, E. Herz, S. Zschaeck, J. Nadobny, M. Weihrauch, V. Budach, P. Wust, P. Ghadjar Charité Universitätsmedizin Berlin, Clinic for Radiation Oncology, Berlin, Germany Introduction: Capacitive hyperthermia systems are widely used to enhance effects of radiation therapy or chemotherapy, however, less is known regarding their penetration depth in order to assess the effectiveness for superficial and intermediate deep-seated lesions.
Objectives:
To measure specific absorption rate (SAR) profiles in homogeneous phantoms using a capacitive system and compare with an analytical solution for an incident transverse plane wave. Methods: Using two different porcine phantoms with different cross-section thickness (10 cm, 14 cm) we registered SAR-values in various horizontally and vertically distributed points by determination of the temperature rise curves. Heating was applied by use of the Celsius42 TCS system (13,56 MHz) with a forward power of 100 W (diameter of both electrodes 25 cm). SAR-values were compared with calculated SAR profiles (by solving Maxwell'sequations for an ideal transverse plane wave penetrating a homogenous lossy medium for different frequencies) (Fig. 2) . Results: SAR profiles showed a 50% SAR reduction in a depth of 2.8-3.3 cm compared to the SAR measured on the phantoms surface in two different porcine phantoms (Fig. 1) . Calculation of the penetration of an ideal transverse plane wave in the frequency range comparable to that used by local microwave applicators (433-200 MHz) results in a 50% SAR depth of only 0.3-0.7 cm. Clearly, for lower frequencies the plane wave solution improves as well (4.5 cm for 30 MHz). However, in this frequency range radiating applicators have unpractical large dimensions (Fig. 2) . Therfore, adequate heating of lesions in a depth of several cm (with half SAR in 3 cm and still ¼ of SAR in 6 cm depth) seems to be better accessible by capacitive systems. On the other hand, inhomogeneity might severely disturb the pattern using the capacitive tchnology, possibly more than for microwave or radiowave applicators. 
Conclusion:
The SAR-distribution in a homogeneous phantom using a capacitive system appears to be suitable for superficial and intermediate deep-seated tumors. Introduction: Nowadays promising way to improve the survival of patients with brain cancer is to overcome the radio-resistance of high grade tumors. According to the modern point of view, hyperthermia (HT) is the universal and most effective radio-and chemo-modifier [1, 2] . Taking into account firstly the negative consequence of the healthy brain tissue overheating and secondly the positive effect of tumor heating it is necessary to control the temperature distribution in brain during the HT session [1] . The invasive measurement techniques are not applicable in this case because of the high risk of complications. Another approach is magnetic resonance thermometry is time-consuming and very expensive. One of the most promising ways is to use a dummy with a "volume process" including a simulation of high grade tumor and healthy brain tissue. Objectives: Present work was dedicated to heterogeneous brain dummy creation including healthy tissue, cerebrospinal fluid and viable high grade tumor. This dummy is suitable for thermometric measurements of HT sessions of post-operative brain tumor treatment in combination with radiation therapy.
Materials and methods:
The Celsius TCS system for local HT was used for treatment delivery. This system for high-frequency HT uses electromagnetic fields and is based on the principle of capacitative coupling [2] . For the purposes of this research, a heterogeneous dummy simulating the real electrical properties of healthy brain tissues, cerebrospinal fluid and high grade tumor was created. For skull creation a fused deposition method was used. Temperature shift measurements were carried out according to the HT recommendations for brain tumors treatment on Celsius TCS system. The online temperature monitoring was carried out by 4-channel measurement device TempSens (Canada) [2] . Results: Performed experiments show that the maximum temperature increase for the areas corresponding to the healthy brain tissue and cerebrospinal fluid were not significantly different and equal to 8 °C.
The temperature increase was 10 °C for the high grade tumor dummy.
Conclusion:
The obtained results shows that proposed approach for temperature distribution measurements using developed brain dummy is very promising for estimation of efficiency and safety of the high-frequency HT sessions. Introduction: Loco-regional hyperthermia treatments are applied in our clinic since many years as additional therapeutic modality to radio-chemotherapy. Local hyperthermia is performed with an external applicator, such as spiral antenna SA-115 and regional hyperthermia is performed with a multi-dipole antenna-pairs applicator, such as Sigma-60 (BSD Medical Corp. currently Pyrexar Medical, Salt Lake City USA). Objectives: As a need of technical aspect of quality assurance in hyperthermia oncology, our objective is to evaluate characteristic parameters of current hyperthermia applicators, predicting possible malfunctions and optimizing a hyperthermia treatment. Knowledge of electric field (E-Field) and specific absorption rate (SAR) distributions in homogeneous phantoms can be used for characterization, improvement and development of hyperthermia applicators.
Materials and methods:
A customized electromagnetic field measurement system developed by Kapteos Company (Sainte-Helene du Lac, France) is used to measure the three electric field components (Ex, Ey, Ez) of the electric field vector, |E|. The spiral antenna applicator (SA-115) is operated with a power of 100 W at 115 MHz frequency. The Sigma-60 applicator is operated with a power of 300 W at 90 MHz frequency with target [0, 0] without any offset settings of amplitude and/or phase of the dipole-antenna pairs. Results: Volumetric SAR distribution with an overlay of the isosurface at 0.5 of the SAR max. reveals an effective field size with 12 cm along x-axis and 12 cm along y-axis, and an effective penetration depth of 3.5 cm below the SA-115 applicator surface.Volumetric SAR distribution of Sigma-60 applicator with an overlay of the isosurface at 0.75 of the SAR max. shows a cylindrical heating volume with 14 cm along z-axis, 10 cm along x-axis and 11 cm along the y-axis. Conclusion: Both hyperthermia applicators demonstrate the ability to generate heating patterns that are in good agreement with physical reasoning based on the assumed electromagnetic behaviour of the two hyperthermia applicators. The 3D E-field measurements provide important visualization of electric field focus and SAR pattern produced in a phantom similar to patient body geometry and dielectric constants. 
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14 years fever-range whole body hyperthermia in adjuvant recurrence prophylaxis of breast cancer
S. Wey
Gemeinschaftspraxis Dr. Wey und Sokolowski, Lauf, Germany
Introduction: In the concept of biological cancer therapy fever range whole body hyperthermia (wbh) plays an important role, but mostly in palliative situation. In the early adjuvant setting, there are only few data.
Objectives: Since 2002 a group of patients is observed, that was treated adjuvant at mostly moderate or high risk constellation after R0 resection with at least two fever range wbh and complementary based therapies. The presentation gives an overview on the immunological importance of fever (e. g. rare in cancer patients, spontaneous remissions after fever), research on hyperthermia-induced tumor perfusion, changes of immunological effector cells (NK cells, dendritic cells, tumor-infiltrating cells) and HSP production. Can tumor patients profit from wbh series in an adjuvant setting concerning tumor survival? Patients and methods: The largest group are women after breast cancer surgery, n = 50. With a few exceptions, the patients had moderate to high relapse risk. Some patients had previously rejected conventional adjuvant therapies. In a single arm, prospective monocentric study they recevied a number of 2-20 wbh up to 40 °C after surgery and adjuvant conventional treatments. Every 24 months the study population is evaluated for disease free and overall survival. Results: A recent (9-2016) evaluation in the recurrence prophylaxis shows a 5-year tumor free survival of > 90% (29/32) and an overall survival of > 96% (31/32). Only 1/32 patients died 7.7 years after FD of breast cancer. The data are discussed in the context of the risk constellation, frequency of hyperthermia and time after primary diagnosis. Statistically, after complete conventional therapy alone, <70% 5-year tumor free survival and an overall survival of <75% would have been expected.
Conclusion:
In the tumor follow up this approach of complementary basic therapy in combination with fever range wbh should be more appreciated and evaluated. Introduction: In the concept of biological cancer therapy fever range whole body hyperthermia (wbh) plays an important role, but mostly in palliative situation. In the early adjuvant setting, there are only few data. Objectives: Can Malignant Melanoma patients after R0 resection profit from at least two or more wbh series in an adjuvant setting concerning tumor survival? Do they have a second chance after treatment of first metastases (tertiary)? Patients and methods: I reporte about three patients after primary malignat melanoma surgery with high reccurence risk according to their sentinel lymph node status and/or Clark level (2 × Clark Level IV and Sentinel LK pos., 1 × Clark Level IV-V, N0). In a single arm, prospective monocentric study the three patients recevied a number of 2-20 wbh up to 40 °C after surgery without other adjuvant conventional treatments. Every 24 months the study population is evaluated for disease free and overall survival. Then I reporte about a now 51-year-old patient who was operated 2/13, tumor formula pT4b, pN2a, stage IV (AJCC 2009). Already 8/13 evidence of a singular brain metastasis on the right parietal and 9/13 1 × therapy with radiosurgery (cyber knife 20 Gy). Decision to carry out fever range wbh (9/13-2/15 9x) and other complementary therapies. In questionable evidence of pulmonary metastasis in PET-CT 9/13 only slow progress and in 3/15 lung partial resection with histological confirmation of an MM metastasis. Since then, further fever range wbh (4/15-10/17 9x).
Results:
The three patients from the adjuvant group treated with fever range wbh are still alive with NED since FD for already 92, 77 and 61 months. The patient with tertiary recurrence prevention shows actually NED: 11/17 MR brain and 12/17 S-100 (0.028 µg/l), PET-CT and lymph nodes ultrasound, 1/18 clinically. So, he has now a tumor free survival since lung surgery of 34 months! Conclusion: Adjuvant wbh should be evaluated in MM patients, even after metastases surgery.
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Molecular profiling based metronomic therapy with local hyperthermia in treatment of relapsed refractory infantile fibrosarcoma -case report Introduction: A hyperthermia treatment planning system has been developed that can read a patient model directly from the patient's computed tomography (CT) scans, simulate the treatment on one of several different deep-heating applicators, and then display the results.
Objectives: The purpose of this project is a hyperthermia treatment planning system with the following characteristics:
• The patient model is developed directly from the patient's CT scans.
• The patient"s treatment can be simulated on different applicators, including the Sigma 60, the Sigma 30, and the Sigma Eye.
• The results of the simulations are easily accessible.
• The simulation procedure can be carried out by clinical personnel.
Methods: All of the programs are written in Python, a computer program that has its own graphics and is available free of charge [1] . The EM simulations are carried out using the FDTD method [2] . Results: An example of the model of a patient in a Sigma 60 is shown in Abb. 1. The resulting specific absorption rate (SAR) distribution is shown in Abb. 2. The power focus of the quadrants can be changed and the operator can view different levels in the patient model very easily. Conclusion: All of the simulations described in this abstract, including the accompanying graphics, were done on a Lenova 71015 laptop computer using the Python programming language. Experiments designed to study the combinatorial effects of hyperthermia and irradiation are mainly based on the use of cell lines or animal models. The objective of this study was to establish a method for efficient ex vivo cultivation of small skin biopsies and to demonstrate their utility in a wound healing assay for treatment with hyperthermia and subsequent irradiation. Material and methods: Abdominal skin samples of 0.5 × 1 mm were obtained from healthy volunteers by punch biopsies. These were treated with a single dose of hyperthermia +/-irradiation. Subsequently, samples were covered with agarose cups for immobilization. The agarose cup enhances the contact between the tissue specimen and the growth substrate, thus supporting the outgrowth of keratinocytes as a wound healing assay. Moreover, agarose allows visualization and medium supply of the explants. Keratinocyte outgrowth was quantified after histochemical staining and by measurement of the area covered by the cells. Results: The use of agarose cups for ex vivo cultivation of skin microbiopsies resulted in a 100% take rate for untreated samples. The explants were cultivated for two to three weeks and yielded an average keratinocyte layer > 100 mm 2 . Hyperthermia at 42 °C for 1 hour did not significantly affect keratinocyte growth. Irradiation with 4 or 6 Gy reduced keratinocyte growth dose-dependently. The combination of hyperthermia and irradiation did not result in enhanced radio-sensitivity of the normal skin explants. Conclusion: This method represents a wound healing assay for very small tissue samples. Skin specimen are not subjected to additional manipulation and treated immediately after biopsy. This assay allows functional studies of combined treatment modalities.
References
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Immunogenic cell death during maintenance chemotherapy and subsequent multimodal immunotherapy for GBM S. van Gool, J. Makalowski, V. Schirrmacher, W. Stuecker
Immun-Onkologisches Zentrum Köln, Translational Oncology, Köln, Germany Introduction: Multimodal immunotherapy is emerging as new treatment modality for patients with GBM. Objectives: To study the effect of multimodal immunotherapy as part of first line treatment for patients with primary GBM.
Patients and methods:
In a retrospective analysis of 56 patients with primary diagnosis of GBM, we detected 20 patients in whom Newcastle Disease Virus (NDV) and modulated electrohyperthermia (mEHT) were added at days 8/9/10 during TMZ maintenance (TMZm) cycles, multimodal NDV/mEHT/DC vaccinations were administered after TMZm, and further NDV/mEHT treatments were given thereafter. Median age was 57.5 years (ranging 17 till 67y, one 7-year old child with gliosarcoma). KPI was >70 (50 for one 17-year old patient). Patients were treated with a median of 27 (14-115) NDV infusions, 24 (4-117) mEHT sessions and 2 (0-13) DC vaccinations. Results: Median OS was 25 months with a 3-year long-term OS of 50% (CI95% +26%, -32%). There were no major toxicities for this ambulatory treatment. The group was further divided into subgroup 1: 12 patients adding NDV/mEHT immediately after radiochemotherapy; and subgroup 2: 8 patients adding NDV/mEHT later-on during TMZm cycles. Patient characteristics were equal, as were DC vaccinations, while more NDV/mETH were administered in subgroup 1. The median OS was 37 versus 24 months (p = 0.00119) for subgroup 1 resp. 2.
Conclusion:
The data suggest that addition of immunogeneic cell death (ICD) via NDV/mEHT during TMZm might be beneficial in controlling disease progression. While TMZm only targets dividing tumor cells most when MGMT is methylated, ICD via NDV and mEHT targets both dividing but also non-dividing tumor cells. Objective: The objective of this study is to design a novel 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG 2 )-based cationic TSL formulation (DPPG 2 -CTSL), which will be used in a comparative study with a previously reported polyethylene glycol (PEG)-based cationic TSL (PEG-CTSL). Nanoparticles binding capability and Doxorubicin (DOX) delivery efficiency were investigated in different cell lines. Furthermore, TSLs were incubated in serum to establish protein adsorption to the surface of these particles. Resulting protein-corona TSLs (P-TSLs) were fully characterized and used in comparative cell binding study against not-serum exposed TSLs. Methods: Liposomes were prepared by film hydration/extrusion method and DOX encapsulation was performed via active loading. TSLs were characterized by dynamic light scattering, differential scanning calorimetry and thin layer chromatograph. Temperature/time dependent DOX release assays were performed by fluorescence spectroscopy. Interactions of (C)TSL with cells were investigated in vitro, by flow cytometry and fluorescence microscopy. Results: ζ-Potential analysis showed higher overall positive surface charge for DPPG 2 -CTSL, when compared to other (C)TSLs (5.5 ± 2.3 mV-physiological condition). DPPG 2 -CTSL had a more performant (2.5 folds) binding potential to all above mentioned cell lines when compared to PEG-CTSL. Furthermore, cells exposed to 50 µM liposomal-DOX showed 1.8 folds higher DOX uptake when treated with DPPG 2 -CTSL, in comparison to PEG-based CTSL. Protein absorption reduced CTSL binding by ≥60% compared to CTSLs that were not serum exposed. Nine patients (42,8%) had to hold therapy due to neutropenic fever (5), pain (2), rush (1), pneumonia (1) and thrombophlebitis (1) . Five of the patients (23,8%) discontinued the therapy due to progression (1), ascites development (2), icterus (1) and severe abdominal pain (1). CEA and CA19-9 levels in pancreatic cancer patients are not predictive for response to mEHY therapy. Conclusion: Twenty-one pancreatic cancer patients were treated at our mEHY therapy unit. Patients with oligometastatic/inoperable tumors are likely the target population of this treatment approach, especially supplementing systemic therapy. CEA and CA19-9 levels in are not predictive for response to mEHY therapy in our cohort. Identification of better biomarkers is warranted. Introduction and objectives: Modulated electro-hyperthermia (mEHT), is a particular kind of hyperthermia in oncology. It considers the heterogeneous structure of the tumor and provides selective thermal actions instead of the homogenous heating. Its advantages are the stable safety, extra low toxicity and systemic effect of the local treatment. The systemic effect is made by the development of the immunogenic celldeath and produces an abscopal effect, excluding the relapse of the same tumor in the system. Our presentation intends to show the clinical studies of mEHT in variously advanced primary and metastatic malignancies. Materials and methods: The collected results are by well-known and widely applied evidence-based medicine. Prospective Phase II and Phase III oncothermia trials exist, together with some retrospective studies. All the retrospective data are compared to large databases and/ or historical arms, and many are compared to the multiple clinical practices making statistical evidence of the validity of the data. Multiple clinical studies are in progress at various university research centers including preparation of one FDA controlled trial in the USA. Results: Such sensitive organs like the brain were successfully treated even with high dose mEHT without extra side effects. The clinical advantages of glioma treatment show important addition to the survival time like it is shown recently in. The small and non-small lung cancer were also successfully treated with mEHT, even in advanced cases.
The gastrointestinal malignancies are also treated successfully with the mEHT method. The liver metastases in colorectal tumors, the primary hepatocellular carcinoma, pancreas carcinoma and unresectable biliary cancer were clinically examined with positive results; in gynecology for ovary, for breast and in cervix. Bone metastases, sarcomas, and even the mEHT treatment of malignant ascites proof the theoretical and experimental results in clinical practice. Conclusion: mEHT has good clinical achievements in the clinical studies making the stable basis of the clinical applications in various advanced primary and metastatic malignancies. symptomatic lesions. We perform HT to offer another treatment choice to advanced oncological diseases previously (or not) previously irradiated. We want to evaluate the safety, feasibility and toxicity of RT-HT in this cohort of patients. Methods: 43 pts (mean age 69 years; range: 47-95) were treated: 21 breast carcinoma, 11 H&N cancer, 3 malignant melanoma, 4 sarcomas, 1 uterine adenocarcinoma, 1 hepatocarcinoma, 2 pancreatic carcinoma and 1 small cell cancer of thigh. The treated lesions were 67. 73% of pts received a previous mean RT dose of 50 Gy. RT techniques used were: 3D-CRT (17/42), Arc-Therapy (2/42) or Helical Tomotherapy (23/42). EBRT was delivered in 5-30 fractions of 1.7-5 Gy to a total dose of 20-63 Gy (mean: 40.3 Gy). HT was performed with a double electromagnetic superficial applicators operating at the frequency of 434 MHz by ALBA double unit. HT session was delivered once/twice weekly, 1-2 hours after RT (range: 1-10 sessions, mean: 5). Average, maximum and minimum temperature parameters were recorded during HT treatment. The treatment goal was to reach 40-42 °C in > 90% (T90) of measured points for a duration of 60". Acute and late toxicity were evaluated according to the CTCAE criteria, Local control (LC) on the basis of the RECIST Criteria. Results: The median temperature reached was 40.5 °C (39-42.9 °C). 5 pts interrupted the treatment: 2 pts (5%) for G3 toxicity, 2 (5%) for poor compliance and 1 (2,4%) for clinical progression. 2 pts (5%) had acute cutaneous toxicity ≥ G3 at 1 month, 4 pts had toxicity > G2 at 3 months, 3 pts after 6 months and only 1 at 12 months. The mean follow-up was 13 months (range 1-50). The LC was: 88%, 78%, 68%, 61%, 71% and 75% at 1, 3, 6, 12, 24, 36 months respectively. The mean time to local progression was 8 months (range 1-36). The detailed results are reported in Table 1 . 10 patients dead (9 for disease and one for vascular accident). Univariate analysis showed that Tmean, Tmax, Tmin, T90 parameters were not associated with local control rate. Conclusion: RT-HT showed a good LC and patient compliance. The clinical outcome and the duration of the follow-up is affected by the advanced stage of diseases. A larger pool and a more detailed stratification are needed. Introduction: When modeling therapeutic applications of FUS, the transducer is typically modelled by modeling the transducer surface geometry and imposing a pressure or velocity boundary condition (depending on the solver type). However, during experimental validation of transcranial FUS modeling, dramatic deviations between simulated and measured pressure distributions were observed that were shown to originate from transducer modeling. Objectives: A systematic study was performed to investigate the impact of factors to be considered to obtain realistic models of acoustic exposure by US transducers. Materials and methods: Acoustic pressure fields generated by curved single-element focused transducers (0.5 MHz) in the presence and absence of skull obstacles (pig, sheep, and lamb; characterized by CT and precisely positioned) have been measured using a 3D-scannable, calibrated hydrophone and compared to acoustic simulations of corresponding setup models. Initially the source was modelled as pressure boundary condition imposed on the transducer surface according to the manufacturer specifications. Subsequently, the model was adapted to consider the actually measured geometry, the internal structure of the transducer (planar piezoelectric disk below a shaped matching material), uncertainty about the internal transducer geometry and material properties, and an aperture function accounting for the mechanical impact of, e. g., the transducer wall. Results: The pressure field sensitivity to the above factors was investigated and after careful model adaptation, good agreement between the simulated and measured fields was obtained in the absence of skulls. Significant deviations are still observed in the presence of skulls and current work focuses on establishing whether they originate from transducer modeling, or from the employed mapping of CT data to acoustic property distributions. Conclusion: Careful transducer modeling and experimental validation is crucial to reliably simulate FUS fields and common approaches are found to be unsuitable for extended, curved or complex transducers. Introduction: The aim of this work was to evaluate the accuracy and reliability of a treatment planning software (SigmaHyperPlan TM ). The temperatures obtained by the planning software were compared with direct invasively measured temperatures within the tumor volume of patients with high-risk soft-tissue sarcoma (STS) located in the extremity region. Methods: Five patients underwent CT fluoroscopy-guided closedtip catheter intratumoral implementation for the invasive thermometry. The invasively measured temperatures were analyzed within the steady-state therapy time by calculating the index temperatures T90, T50 and T20 as well as Tmean, Tmin and Tmax. Furthermore, the thermal dose (CEM43T90) of T90 was determined from the invasive measured temperature. The simulated data from the planning software were evaluated in a similar manner to the measured data by computing index temperatures, except for CEM43T90. Finally, the relative error of the index temperatures between the simulation and the measurement was calculated in order to determine the difference between both approaches. Results: The invasive thermometry data showed a heterogeneous temperature distribution along all catheters within the tumor volume, while the simulated temperatures were nearly homogeneous. In the temperature range of 38 °C to 47 °C, the five STS patients showed different measured temperature behaviors depending on the tumor characteristic. The CEM43T90 results showed higher values for fast heated tumors and lower values for slow heated ones depending on the tumor blood perfusion. On the other hand, the simulations indicated nearly homogeneous temperature distribution with higher temperatures than invasive thermometry. The global error of the index temperatures between simulation and invasive temperature measurement was found to be ±22%. Conclusion: No good agreement was found between the invasive thermometry and thermal simulations regarding the temperature distribution in these tumors due to limitations in both methods. of the 25% iso-SAR volume (TC25) and clinical outcome for superficial hyperthermia (HT) [4] . Objectives: The correlation between THQ and TC25 and predicted T50 was studied for head&neck HT. Patients and methods: Patient specific treatment planning results of twelve patients for the HYPERcollar3D were selected. Avoiding optimization bias, both the clinical method and focusing via constrained power optimization [5] were used. Results: Fig. 1 shows a good correlation between TC25 and T50 (R 2 = 0.65) and no correlation between THQ and T50 (R 2 = 0.00). Although THQ might still serve as optimization coefficient [3] , it might not be predictive for T50. Compared to DPH, the higher THQ values show a more target conformal heating. Conclusion: These preliminary results indicate a different SAR-temperature relation for target conformal HT devices. Further work aims at revealing the tissue property uncertainties and modelling effect.
Introduction: Nanosized hydrogels (nanogels) are soft and highly crosslinked polymer networks that can hold a large amount of water and drugs as cargo. Nanogels can be modified to be sensitive to environmental conditions like pH, temperature changes or magnetic fields, and respond with change in size. We develop different thermoresponsive nanogels as drug delivery systems that collapse upon increased temperature. Moreover, we modify thermoresponsive nanogels with a second, interpenetrated polymer network or nanoparticles which can absorb near infrared (NIR) light and generate heat. This enables a directed heating and thermal treatment of (tumor-)tissue containing accumulated nanogels only at the site of NIR irradiation [1, 2] . Objectives: We develop thermoresponsive nanogel systems and evaluate their applicability for thermal ablation of cells and tissues. Materials and methods: Different functional nanogels were exposed to cells in culture and their metabolic activity and cellular uptake was studied using MTT Test and confocal microscopy. Nude mice were treated with increasing doses and their weight and blood was monitored. Tumor cells treated with nanogels were irradiated with NIR light and the development of heat was monitored with a thermal camera, as well as their thermal ablation was studied in vitro and in vivo. Results: Different thermoresponsive nanogels were synthesized and heat generation upon NIR irradiation was shown. Preparations did not have adverse effects on cell proliferation up to a concentration of 1 mg/ ml in vitro and were well tolerated in the nude mouse model in short and long-term application of 100 mg/kg. Tumor cells treated with nanogels semi-interpenetrated with NIR transducers showed a concentration dependent temperature increase up to 20 °C upon irradiation, leading to thermal ablation. In a mouse model, tumor size was reduced to about 50% at 10 days after one-time NIR irradiation as compared to the control. Conclusion: Thermoresponsive and light-to-heat transforming nanogels show great potential to be used as heat generating agents in biomedical applications. Conclusions: ODLH is a safe synergistic oncologic treatment in the advanced tumor setting. We have not seen any toxicity in our short experience. Acceptance of patients and regional oncology specialists has been a key of success. These results encourage us to engage our efforts towards a broad application of hyperthermic treatments and to initiate clinical studies to determine favorable clinical settings for the use of hyperthermia. Keywords: Hyperthermia, Oncology, Cancer, Metastases, Combined oncology treatments
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Whole body thermochemotherapy -a treatment passing into silence?
A. Herzog Fachklinik Dr. Herzog, Bad Salzhausen, Germany Introduction: While different techniques of local hyperthermia are intensively researched and used in more and more countries whole-bodyhyperthermia is becoming gradually marginalized. Objective: To provide a literature overview on the evidence for whole body hyperthermia for different cancer entities. Material and methods: A literature search was performed for publications on whole body hyperthermia and cancer. Results: Data was identified for breast cancer, ovarian cancer, metastatic colorectal cancer, pancreatic cancer, metastatic prostate cancer and metastatic sarcoma. Conclusion: Many old studies showing good and promising results for whole body hyperthermia where identified.
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The successful antibiotic augmented thermal eradication of chronic lyme disease F. R. Douwes Clinic St. Georg, Bad Aibling, Germany Introduction: It is scientifically proven that the Borrelia burgdorferi bacterium is thermolabile. It is killed at a temperature of 41.6 °C. The thermolability is scientifically proven. Systemic whole-body hyperthermia (SGHT) not only kills the Borrelia, but also activates the body's immune system, especially macrophages and natural killer (NK) cells. This allows the bacteria to be eliminated. In addition, the activity of antibiotics is increased about 16 times by a temperature increase, e. g. per 2 degrees. Objectives: In my presentation, I explain the effectiveness of the "Antibiotics Augmented Thermoeradication" (AAT) we have developed for the treatment of patients with chronic Borrelia infection and its late sequelae. Material and methods: We have successfully treated more than 800 chronic Lyme disease patients with AAT and have seen drastic improvements as AAT kills the Borrelia wherever they are in the body, immediately halting the production of neurotoxins. For the elimination of neurotoxins, we have developed our own and individually adapted detoxification programs. The endocrine disorders commonly present in chronic Lyme disease, such as endocrine disorders, hypothyroidism or adrenal insufficiency must be eliminated as well as sexual disorders.
Results:
The almost always present intestinal symbiosis (leaky good) can also be recognized and treated.
Because the chronic Lyme disease causes multifunctional disturbances and can imitate almost all clinical patterns, the therapy must also be complex.
Conclusion:
The focus is on the elimination of Borrelia by the SGHT in combination with antibiotics, everything else is then a cura posterior, which ensures the success achieved by the whole body hyperthermia and leads the patients back to life after a long history of suffering, to a life without Lyme disease.
